To bring disruptive technologies in health, environment and sustainability, and biomanufacturing to market.
Most of our team has advanced training in science and our international Science Advisory Board is award-winning. We scout for ambitious SynBio projects and run pitch competitions to support the best in the field.
Spans many niche areas of SynBio research and commercialization across Europe. We nurture it through our Annual SynBio Day, pitch competitions, and participation to workshops and conferences.
We are 100% dedicated to investment in projects that use synthetic biology in the most innovative ways. We’re convinced that European research has immense potential to be exploited for the greater good.
Our investments span health, environment and bio-manufacturing. We support ventures at different stages of their development to maintain a balanced portfolio.
Synthetic biology applies techniques from engineering and computer sciences to biology. We believe it will revolutionize how we live, eat, and protect our planet.
of the materials we use could be made using biology
use cases with applications in healthcare, manufacturing, agriculture, energy and the environment
is the estimated value projection of direct economic impact of SynBio innovation by 2040
We act as a bridge between academia and industry, financing and developing synthetic biology innovation across Europe, UK, and Israel through an innovative investment model geared towards very early-stage start-ups and more mature SynBio companies.
We’re convinced that the right SynBio innovations will provide solutions to major challenges of our time.
Stay up to date with our latest news and events.
eureKING has a clear and identified roadmap to bolster Skyepharma’s technology platform to consolidate the highly fragmented European market in biomanufacturing capacity, such as state-of-the-art facilities to manufacture cell and gene therapies in Europe.
The European project will enhance the commercial potential of one of today’s most disruptive fields
eureKARE announces EonBio as the second company to be supported by its Belgium biomedical start-up studio
Ms. Lauvergeon brings an extensive background in the management of large energy corporations (most notably as CEO of Areva), finance, and government.
Innovative gene circuit technology has the potential to detect and treat cancerous and other diseased cells
Authored by eureKARE: Alexandre Mouradian (Chairman, Co-Founder and CEO)